Hybrid Molecular Imaging in Differentiated Thyroid Carcinoma.

2区医学 Q2 Medicine

Frontiers of Hormone Research Pub Date : 2016-03-15 DOI:10.1159/000442276

D. Schmidt, T. Kuwert

{"title":"Hybrid Molecular Imaging in Differentiated Thyroid Carcinoma.","authors":"D. Schmidt, T. Kuwert","doi":"10.1159/000442276","DOIUrl":null,"url":null,"abstract":"Radioactive isotopes of radioiodine are frequently used in differentiated thyroid carcinoma (DTC) both for diagnosis and therapy. Their accumulation in thyroid cancer tissue is dependent on the expression and activity of the sodium-iodide symporter (NIS). Scintigraphic imaging using either planar or single-photon emission computed tomography (SPECT) cameras allows the visualization of their distribution within the human body. Due to only a poor visualization of morphology by these techniques, their diagnostic accuracy is, however, limited. This limitation is overcome when hybrid systems integrating a SPECT camera with an X-ray CT scanner are used. Roughly one third of patients with diagnostically unclear foci of radioiodine accumulation will benefit from the use of SPECT/CT, also in terms of therapeutic management. SPECT/CT has, therefore, become the gold standard of nuclear imaging in DTC. NIS expression may be absent in DTC. In this case, the glucose transporters are usually upregulated. Therefore, PET/CT using 18F-deoxyglucose can be used to diagnose and localize tumor recurrence as a prerequisite to, in particular, surgical intervention.","PeriodicalId":50428,"journal":{"name":"Frontiers of Hormone Research","volume":"45 1","pages":"37-45"},"PeriodicalIF":0.0000,"publicationDate":"2016-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000442276","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers of Hormone Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000442276","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 3

Abstract

Radioactive isotopes of radioiodine are frequently used in differentiated thyroid carcinoma (DTC) both for diagnosis and therapy. Their accumulation in thyroid cancer tissue is dependent on the expression and activity of the sodium-iodide symporter (NIS). Scintigraphic imaging using either planar or single-photon emission computed tomography (SPECT) cameras allows the visualization of their distribution within the human body. Due to only a poor visualization of morphology by these techniques, their diagnostic accuracy is, however, limited. This limitation is overcome when hybrid systems integrating a SPECT camera with an X-ray CT scanner are used. Roughly one third of patients with diagnostically unclear foci of radioiodine accumulation will benefit from the use of SPECT/CT, also in terms of therapeutic management. SPECT/CT has, therefore, become the gold standard of nuclear imaging in DTC. NIS expression may be absent in DTC. In this case, the glucose transporters are usually upregulated. Therefore, PET/CT using 18F-deoxyglucose can be used to diagnose and localize tumor recurrence as a prerequisite to, in particular, surgical intervention.

查看原文本刊更多论文

分化型甲状腺癌的杂交分子显像。

放射性碘的放射性同位素常用于分化型甲状腺癌(DTC)的诊断和治疗。它们在甲状腺癌组织中的积累依赖于碘化钠同调体(NIS)的表达和活性。使用平面或单光子发射计算机断层扫描(SPECT)相机的闪烁成像可以可视化它们在人体内的分布。然而，由于这些技术的形态学可视化效果很差，其诊断准确性受到限制。当使用集成SPECT相机和x射线CT扫描仪的混合系统时，可以克服这一限制。大约三分之一的放射性碘积聚灶诊断不明确的患者将受益于SPECT/CT的使用，也在治疗管理方面。因此，SPECT/CT已成为DTC核成像的金标准。DTC中可能没有NIS的表达。在这种情况下，葡萄糖转运蛋白通常被上调。因此，使用18f -脱氧葡萄糖的PET/CT可作为诊断和定位肿瘤复发的先决条件，特别是手术干预。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Frontiers of Hormone Research 医学-内分泌学与代谢

自引率

0.00%

发文量

期刊介绍： A series of integrated overviews on cutting-edge topics New sophisticated technologies and methodological approaches in diagnostics and therapeutics have led to significant improvements in identifying and characterizing an increasing number of medical conditions, which is particularly true for all aspects of endocrine and metabolic dysfunctions. Novel insights in endocrine physiology and pathophysiology allow for new perspectives in clinical management and thus lead to the development of molecular, personalized treatments. In view of this, the active interplay between basic scientists and clinicians has become fundamental, both to provide patients with the most appropriate care and to advance future research.